Try

MacroGenics Inc. Common Stock

MGNXUnited States

5 filed reports · 226 financial concepts · 4 earnings calls · 0 media appearances

Filed reports

5 reports · Jun 2025 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR4737Jun 2025 to Jun 2026
Annual · 10-KSEC EDGAR1612Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 14, 2026287Open
FY2026 Q110-QMar 31, 2026May 13, 2026171Open
FY202510-KDec 31, 2025Mar 9, 2026612Open
FY2025 Q310-QSep 30, 2025Nov 12, 2025205Open
FY2025 Q210-QJun 30, 2025Aug 14, 202574Open

Financial data

226 concepts · 1,349 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial218 concepts · 1,264 facts · Dec 2023 to Jun 2026

  • Stockholders equity including portion attributable to noncontrolling interest14 · Dec 2023 to Jun 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
  • Net income loss13 · Dec 2023 to Jun 2026
  • Stock plan related activity13 · Dec 2023 to Jun 2026
  • Unrealized gain loss on investments13 · Dec 2023 to Jun 2026
  • Allocated share based compensation expense12 · Dec 2023 to Jun 2026
  • Comprehensive income net of tax12 · Dec 2023 to Jun 2026
  • Costs and expenses12 · Dec 2023 to Jun 2026
  • General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
  • Operating income loss12 · Dec 2023 to Jun 2026
  • Other comprehensive income loss available for sale securities adjustment net of tax12 · Dec 2023 to Jun 2026
  • Research and development expense12 · Dec 2023 to Jun 2026
  • Revenue12 · Dec 2023 to Jun 2026
  • Accretion amortization of discounts and premiums investments11 · Dec 2023 to Jun 2026
  • Capital expenditures incurred but not yet paid11 · Dec 2023 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
  • Cost of manufacturing services11 · Dec 2023 to Mar 2026
  • Depreciation depletion and amortization11 · Dec 2023 to Jun 2026
  • Increase decrease in accounts receivable11 · Dec 2023 to Jun 2026
  • Increase decrease in accrued liabilities11 · Dec 2023 to Jun 2026
  • Increase decrease in contract with customer liability11 · Dec 2023 to Jun 2026
  • Increase decrease in inventories11 · Dec 2023 to Jun 2026
  • Increase decrease in other operating assets11 · Dec 2023 to Jun 2026

Product1 concepts · 43 facts · Dec 2023 to Jun 2026

  • Revenue43 · Dec 2023 to Jun 2026

Segment7 concepts · 42 facts · Dec 2023 to Jun 2026

  • Segment reporting other item amount12 · Dec 2023 to Jun 2026
  • General and administrative expense (US GAAP)6 · Sep 2024 to Jun 2026
  • Net income loss6 · Sep 2024 to Jun 2026
  • Research and development expense6 · Sep 2024 to Jun 2026
  • Revenue6 · Sep 2024 to Jun 2026
  • Cost of manufacturing services4 · Sep 2024 to Mar 2026
  • Cost of goods and services sold (US GAAP)2 · Sep 2024 to Sep 2025

Segments

85 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service5 members · 43 facts

  • Revenue From Collaborative Agreements12 · Dec 2023 to Jun 2026
  • Contract Manufacturing11 · Dec 2023 to Mar 2026
  • Product9 · Dec 2023 to Dec 2025
  • Revenue From Royality Agreements Member7 · Dec 2023 to Jun 2026
  • Government Contract4 · Jun 2024 to Sep 2025

Statement business segments1 member · 42 facts

  • Main42 · Dec 2023 to Jun 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

4 calls · Mar 2024 to Mar 2025

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2024 Q4Mar 20, 2025
  • FY2024 Q2Nov 5, 2024
  • FY2024 Q1May 9, 2024
  • FY2023 Q4Mar 7, 2024

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

MacroGenics Inc. Common Stock (MGNX) data · FactIQ